A study to test how BI 764532 is taken up by tumours in people with small-cell lung cancer or neuroendocrine cancer
Phase 1
- Conditions
- euroendocrine carcinoma (NEC) or small cell carcinoma of any otherorigin, Small cell lung carcinoma (SCLC), Large cells neuroendocrine lung carcinoma (LCNEC)MedDRA version: 21.0Level: LLTClassification code: 10048683Term: Advanced cancer Class: 10029104Therapeutic area: Diseases [C] - Neoplasms [C04]
- Registration Number
- CTIS2022-501818-54-00
- Lead Sponsor
- Boehringer Ingelheim International GmbH
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method